Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: RETRACTED ARTICLE: α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway

Figure 5

α-santalol inhibits the phosphorylation VEGFR-2 and inhibits the activation of VEGFR2-mediated downstream signaling. (A) α-santalol inhibits the phosphorylation of VEGFR-2. HUVECs were pre-treated with α-santalol followed by the stimulation with 50 ng/mL of VEGF for 2 min. (B) Quantitative densitometry of phosphoTyr1175-VEGFR- 2/VEGFR-2 is shown as percentage (%) of control. Values are mean ± SEM (n = 6) of three independent experiments. (C) α-santalol decreased VEGF levels in HUVEC and PC-3 cells as determined by sandwich ELISA following the manufacturer’s instructions (R and D systems, USA). Absorbance was determined using a microplate reader (Biorad, USA) at 450 nm. *p < 0.05; **p < 0.01;***p < 0.001 versus control group. (D) Inhibition of VEGFR2 kinase activity by α-santalol was analyzed using an in vitro HTScan® VEGF receptor 2 kinase kit (Cell Signaling Technology, Danvers, MA, USA) combined with colorimetric ELISA detection according to the manufacturer’s instructions. Values are mean ± SEM (n = 6) of three independent experiments. (E) α-santalol inhibits the activation of VEGFR2-mediated downstream signaling.

Back to article page

Molecular Cancer

ISSN: 1476-4598